The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Sponsor: Hanchuan City people's Hospital
This PHASE2 trial investigates Metastatic Gastric Cancer and is currently ongoing. Hanchuan City people's Hospital leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Aug 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jun 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2023 — Jun 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Oct 2021 — Jan 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2019 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hanchuan City people's Hospital
- Huangshi Central Hospital
- Hubei Cancer Hospital
- Taihe Hospital
- The Central Hospital of Huanggang
- The first hospital of Zaoyang
- Tianmen People's Hospital
- Xianning Central Hospital
- Yangxin People's Hospital
- Zhou Fuxiang
For direct contact, visit the study record on ClinicalTrials.gov .